Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups.
The goals of this study are:
- To measure clinical benefit defined as tumor response or progression-free survival for
more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed
or have progressed on a VEGF receptor inhibitor
- To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney
who have failed or have progressed on a VEGF receptor inhibitor